ArQule Inc. (Nasdaq: ARQL) entered an exclusive license agreement with Basilea Pharmaceutica International to develop and commercialize derazantinub. Shares of the biopharmaceutical gained 46 cents to close at $3.16.
ArQule enters exclusive agreement
April 17, 2018 at 17:29 PM EDT
